Hyderabad, Jul 30 (KNN) Agilent Technologies, a global leader in life sciences and diagnostics, has inaugurated a new Biopharma Capability Center in Hyderabad, marking a major step in its expansion strategy for India over the next three to five years.
This facility is aimed at enhancing India’s role in global biopharma innovation and drug development.
The center was launched by Telangana’s IT and Industries Minister Duddila Sridhar Babu, alongside Agilent’s global CEO Padraig McDonnell.
Equipped with advanced lab technologies, training modules, and regulatory-ready workflows, the center is designed to support the full drug development lifecycle, especially in biologics, biosimilars, and precision medicine.
Offering end-to-end solutions in chromatography, mass spectrometry, cell analysis, and lab informatics, the center enables real-world lab simulations, quality testing, and co-creation of solutions tailored for both Indian and international markets.
Hyderabad’s startups, researchers, and academic institutions will benefit from hands-on training, global expertise, and access to state-of-the-art equipment, enhancing R&D capabilities and industry-academia collaboration.
“India is a strategic growth market for us, and Hyderabad leads in biopharma innovation,” said McDonnell. “This center reinforces our commitment to ‘Make in India’ by empowering local talent and innovation.”
Minister Sridhar Babu praised the center as a vital addition to Telangana’s thriving life sciences ecosystem, which contributes nearly 30 per cent of India’s pharmaceutical output and 40 per cent of bulk drug exports.
This move follows Agilent’s earlier launch of its India Solution Center in Manesar, underlining its intent to make India a central player in its global innovation roadmap. McDonnell added, “We’re working closely with leading Indian biopharma firms to co-create solutions for evolving global and local needs.”
(KNN Bureau)
